logo-loader
ASX:PTX OTC:PSTTF

Prescient Therapeutics Ltd

 Receive alerts
Market:
ASX
Price
0.05 AUD
Day Change
-1.89%
Market Cap:
$41.88 m
52 weeks high
0.06
52 weeks low
0.04
04.52

Director Interviews

In brief

Prescient Therapeutics Ltd (ASX:PTX) is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.
 

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

Prescient Therapeutics seeks to provide new tools for clinicians in combating cancer
cancer cell

Snapshot

  • Prescient begins PTX-100 Phase 2 Trial for rare lymphoma
  • Prescient Therapeutics: Advancing cancer treatment with PTX-100 and cell therapies
  • Prescient Therapeutics secures speculative buy recommendation from Bioshares
  • Prescient Therapeutics PTX-100 shows promising results in Phase 1b study
Open Deep dive

Latest news

Prescient begins PTX-100 Phase 2 Trial for rare lymphoma

2 weeks, 2 days ago

Prescient Therapeutics doses first patient in Phase 2a study of PTX-100 for...

2 weeks, 5 days ago

FDA grants Fast Track status to Prescient’s PTX-100, advancing...

on 04/15/2025

Prescient Therapeutics appoints Melanie Farris to board as non-executive...

on 04/09/2025

Prescient Therapeutics opens first clinical site for Phase 2a PTX-100 trial...

on 03/25/2025

The morning catch up: ASX on the green as small and mid cap companies...

on 03/25/2025

Prescient Therapeutics appoints Dr Marissa Lim as chief medical officer

on 03/23/2025

Prescient Therapeutics to present PTX-100 clinical data at international...

on 03/20/2025

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Oncology market projected to soar in 2025 and beyond Oncology market projected to soar in 2025 and beyond
on 01/22/2025
Feature

Novotech report on small cell lung cancer sector reveals promising treatment progress

on 11/18/2024
What Brokers Say

Prescient Therapeutics nearing a potential payday with PTX-100: Pitt Street Research

on 11/15/2023
Inspired

Challenging the pace of change in healthcare: Prescient Therapeutics

on 08/03/2022

Watch

Prescient Therapeutics targets rare T-cell cancer in new clinical trial, doses first patient Director Interviews Prescient Therapeutics targets rare T-cell cancer in new clinical trial, doses first patient
2 weeks, 4 days ago
Oncology outlook: ASX small caps driving innovation in cancer treatment Director Interviews Oncology outlook: ASX small caps driving innovation in cancer treatment
on 01/23/2025
Prescient Therapeutics Ltd - Just the Facts: Prescient Therapeutics secures FDA approval for PTX-100 Phase 2 trials Small Caps Just the Facts: Prescient Therapeutics secures FDA approval for PTX-100 Phase 2 trials
on 12/22/2024
Prescient Therapeutics Ltd - Prescient Therapeutics PTX-100 shows promising results in Phase 1b study Director Interviews Prescient Therapeutics PTX-100 shows promising results in Phase 1b study
on 05/20/2024
View all
OSZAR »